Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Monoclonal antibody therapies for cutaneous T-cell lymphoma

Pier L. Zinzani • 3 Oct 2015
iwNHL 2015
Cutaneous T-Cell Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Brentuximab vedotin Mogamulizumab

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Pier Luigi Zinzani, MD, PhD, of University of Bologna, Bologna, Italy, discusses the clinical development of the anti-CD30 antibody-drug conjugate brentuximab vedotin and the anti-CCR4 antibody mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals